13,14-dihydroprostaglandin e1 has been researched along with alprostadil in 23 studies
| Studies (13,14-dihydroprostaglandin e1) | Trials (13,14-dihydroprostaglandin e1) | Recent Studies (post-2010) (13,14-dihydroprostaglandin e1) | Studies (alprostadil) | Trials (alprostadil) | Recent Studies (post-2010) (alprostadil) |
|---|---|---|---|---|---|
| 27 | 2 | 3 | 7,136 | 864 | 761 |
| Protein | Taxonomy | 13,14-dihydroprostaglandin e1 (IC50) | alprostadil (IC50) |
|---|---|---|---|
| Multidrug resistance-associated protein 4 | Homo sapiens (human) | 2.3 | |
| Solute carrier organic anion transporter family member 2B1 | Rattus norvegicus (Norway rat) | 0.0358 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 22 (95.65) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Davis, TL; Sharif, NA | 1 |
| Gerakakis, A; Keiler, A; Lupattelli, G; Peskar, BA; Sinzinger, H; Virgolini, I | 1 |
| Leonhardt, A; Schweer, H; Seyberth, HW; Wolf, D | 1 |
| Firbas, W; Neumann, I; Rogatti, W; Sinzinger, H; Virgolini, I | 1 |
| Braun, M; Bruch, L; Ney, P; Schrör, K; Szymanski, C | 1 |
| Hesse, WH; Peskar, BA; Rudofsky, G | 1 |
| Braun, M; Bruch, L; Hohlfeld, T; Ney, P; Schrör, K; Szymanski, C | 1 |
| Fitscha, P; O'Grady, J; Peskar, BA; Rauscha, F; Rogatti, W; Sinzinger, H | 1 |
| Diehm, C; Hesse, WH; Peskar, BA; Rogatti, W; Rudofsky, G; Schweer, H; Seyberth, HW | 1 |
| Fitscha, P; Gerakakis, A; Li, SR; O'Grady, J; Sinzinger, H; Virgolini, I | 1 |
| Cawello, W; Schweer, H; Seyberth, HW | 1 |
| Akarasereenont, P; Hide, E; Ney, P; Thiemermann, C; Vane, JR | 1 |
| Baumann, G; Bruch, L; Kästner, A; Modersohn, D; Ney, P | 1 |
| Bonn, R; Cawello, W; Müller, R; Schweer, H; Seyberth, HW | 1 |
| Meese, CO; Schweer, H; Seyberth, HW; Watzer, B | 1 |
| Pallapies, D; Peskar, BA | 2 |
| Kritz, H; O'Grady, J; Peskar, BA; Rodrigues, M; Rogatti, W; Sinzinger, H | 1 |
| Hide, EJ; Ney, P; Piper, J; Thiemermann, C; Vane, JR | 1 |
| Bräutigam, M; Misselwitz, B | 1 |
| Albrecht, D; Cawello, W; Dietrich, B; Fox, A; Hohmuth, H; Schweer, H; Seyberth, HW | 1 |
| Gallant, C; Goldstein, I; Huang, YH; Moreland, RB; Traish, AM | 1 |
| Neumann, I; O'Grady, J; Peskar, BA; Rogatti, W; Sinzinger, H | 1 |
1 review(s) available for 13,14-dihydroprostaglandin e1 and alprostadil
| Article | Year |
|---|---|
13,14-Dihydro-prostaglandin E1 in atherosclerosis.
Topics: Alprostadil; Animals; Arteriosclerosis; Humans; Male; Platelet Aggregation; Rats; Rats, Wistar | 1993 |
2 trial(s) available for 13,14-dihydroprostaglandin e1 and alprostadil
| Article | Year |
|---|---|
Metabolism and pharmacokinetics of prostaglandin E1 administered by intravenous infusion in human subjects.
Topics: Adult; Alprostadil; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infusions, Intravenous; Male; Single-Blind Method | 1994 |
Pharmacokinetics of prostaglandin E1 and its main metabolites after intracavernous injection and short-term infusion of prostaglandin E1 in patients with erectile dysfunction.
Topics: Alprostadil; Biological Availability; Cross-Over Studies; Erectile Dysfunction; Humans; Infusions, Intravenous; Injections; Male; Middle Aged; Vasodilator Agents | 1997 |
20 other study(ies) available for 13,14-dihydroprostaglandin e1 and alprostadil
| Article | Year |
|---|---|
Pharmacological characterization of [(3)H]-prostaglandin E(2) binding to the cloned human EP(4) prostanoid receptor.
Topics: Binding, Competitive; Cell Line; Cell Membrane; Dinoprostone; DNA, Recombinant; Dose-Response Relationship, Drug; Humans; Ligands; Prostaglandins; Radioligand Assay; Receptors, Prostaglandin E; Receptors, Prostaglandin E, EP4 Subtype; Tritium | 2000 |
13,14-Dihydro-prostaglandin E1 decreases low-density lipoprotein influx into rabbit aorta.
Topics: Alprostadil; Animals; Aorta; Cholesterol; Endothelium, Vascular; Humans; In Vitro Techniques; Lipoproteins, LDL; Male; Rabbits | 1992 |
Formation of biologically active 13,14-dihydro-prostaglandin E1 during intravenous infusion of prostaglandin E1 in newborns with ductus arteriosus-dependent congenital heart disease.
Topics: Alprostadil; Ductus Arteriosus, Patent; Gas Chromatography-Mass Spectrometry; Humans; Infant, Newborn | 1992 |
Prostaglandin (PG) E1 and 13,14-dihydro (DH) PGE1 are diminishing radiation-induced arterial damage.
Topics: Alprostadil; Animals; Aorta, Abdominal; Arteries; Autoradiography; Dose-Response Relationship, Radiation; Extracellular Matrix; Male; Mitosis; Rabbits; Radiation Injuries, Experimental; Radiation-Protective Agents | 1992 |
Antiplatelet, antineutrophil and vasodilating properties of 13,14-dihydro-PGE1 (PGE0)--an in vivo metabolite of PGE1 in man.
Topics: Alprostadil; Animals; Blood Platelets; Glucuronidase; Humans; In Vitro Techniques; N-Formylmethionine Leucyl-Phenylalanine; Neutrophils; Platelet Activating Factor; Rabbits; Superoxides; Vasodilation | 1991 |
[Metabolism of intravenously administered prostaglandin E1 in patients with peripheral arterial occlusive disease].
Topics: Adult; Aged; Aged, 80 and over; Alprostadil; Arterial Occlusive Diseases; Biotransformation; Dinoprostone; Female; Humans; Infusions, Intravenous; Male; Middle Aged | 1991 |
[The pharmacology of 13,14-dihydro-PGE1 in comparison with PGE1].
Topics: Alprostadil; Blood Platelets; Humans; Muscle, Smooth, Vascular; Platelet Aggregation; Platelet Function Tests; Vasoconstriction | 1991 |
13,14-dihydro-PGE1, an in-vivo metabolite of PGE1, decreases mitotic activity induced by corticosteroid administration.
Topics: Alprostadil; Animals; Aorta, Abdominal; Desoxycorticosterone; Mitosis; Rabbits; Stress, Physiological; Thymidine | 1991 |
Formation of 13,14-dihydro-prostaglandin E1 during intravenous infusions of prostaglandin E1 in patients with peripheral arterial occlusive disease.
Topics: Alprostadil; Arterial Occlusive Diseases; Chromatography, High Pressure Liquid; Female; Gas Chromatography-Mass Spectrometry; Humans; Male; Radioimmunoassay | 1991 |
Increase in in vivo low-density lipoprotein (LDL) receptor binding after PGE1 and 13,14-dihydro-PGE1 treatment in rabbits.
Topics: Alprostadil; Animals; Cholesterol, Dietary; Hypercholesterolemia; Liver; Male; Rabbits; Receptors, LDL; Up-Regulation | 1993 |
Gas chromatography/negative ion chemical ionization triple quadrupole mass spectrometric determination and pharmacokinetics of 11 alpha-hydroxy-9,15-dioxo-2,3,4,5,20-pentanor-19-carboxyprostan oic acid in plasma.
Topics: Adolescent; Adult; Alprostadil; Gas Chromatography-Mass Spectrometry; Half-Life; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Prostaglandins | 1994 |
The induction of cyclooxygenase-2 elicited by endotoxin in endothelial cells and macrophages is inhibited by prostaglandin E1 and 13,14-dihydro prostaglandin E1.
Topics: Alprostadil; Animals; Aorta; Blotting, Western; Cattle; Cells, Cultured; Endothelium, Vascular; Lipopolysaccharides; Macrophages; Mice; Prostaglandin-Endoperoxide Synthases | 1995 |
Effects of prostaglandin E1, prostaglandin E0 and SPM 206 on isolated human coronary arteries.
Topics: Alprostadil; Coronary Vessels; Humans; In Vitro Techniques; Muscle Contraction | 1995 |
Determination of prostaglandin E1 and its main plasma metabolites 15-keto-prostaglandin E0 and prostaglandin E0 by gas chromatography/negative ion chemical ionization triple-stage quadrupole mass spectrometry.
Topics: Alprostadil; Gas Chromatography-Mass Spectrometry; Humans; In Vitro Techniques | 1994 |
Effect of prostaglandin (PG) E1 and its initial metabolites on neutrophil-induced inhibition of human platelet aggregation.
Topics: Alprostadil; Animals; Collagen; Drug Synergism; Humans; Male; Neutrophils; Nitric Oxide; Platelet Aggregation; Platelet Aggregation Inhibitors; Rats; Rats, Wistar; Thrombin | 1993 |
PGE0 inhibits collagen and glycosaminoglycan-synthesis in the rabbit arterial wall.
Topics: Alprostadil; Animals; Collagen; Glycosaminoglycans; Male; Muscle, Smooth, Vascular; Platelet Aggregation Inhibitors; Rabbits; Vasodilator Agents | 1995 |
Reduction by prostaglandin E1 or prostaglandin E0 of myocardial infarct size in the rabbit by activation of ATP-sensitive potassium channels.
Topics: Adenosine Triphosphate; Alprostadil; Animals; Anti-Arrhythmia Agents; Biotransformation; Blood Pressure; Decanoic Acids; Electrocardiography; Glyburide; Heart Rate; Hydroxy Acids; Hypoglycemic Agents; Male; Myocardial Infarction; Myocardial Ischemia; Myocardial Reperfusion Injury; Myocardium; Potassium Channels; Rabbits; Vasodilator Agents | 1995 |
A comparative study of the effects of iloprost and PGE1 on pulmonary arterial pressure and edema formation in the isolated perfused rat lung model.
Topics: Alprostadil; Animals; Blood Pressure; Disease Models, Animal; Iloprost; In Vitro Techniques; Male; Organ Size; Perfusion; Pulmonary Artery; Pulmonary Edema; Rats; Rats, Wistar; Reproducibility of Results; Vasodilator Agents | 1996 |
G-protein-coupled receptor agonists augment adenylyl cyclase activity induced by forskolin in human corpus cavernosum smooth muscle cells.
Topics: Adenylyl Cyclases; Alprostadil; Carbachol; Cells, Cultured; Colforsin; Drug Interactions; Enzyme Activation; GTP-Binding Proteins; Humans; Isoproterenol; Male; Models, Biological; Muscle Relaxation; Muscle, Smooth, Vascular; Penis; Phenylephrine; Receptors, Adrenergic, beta; Receptors, Cell Surface; Receptors, Cholinergic; Signal Transduction | 1997 |
Effects of prostaglandin E1 metabolites on the induction of arterial thromboresistance.
Topics: Alprostadil; Animals; Aorta; Arteries; Blood Platelets; Endothelium, Vascular; Humans; Iliac Artery; In Vitro Techniques; Male; Perfusion; Rabbits; Thrombosis | 1998 |